A recent study conducted by digital healthcare provider Voy uncovered that a significant number of Brits who have utilized GLP-1 weight loss medication have chosen to keep it a secret. The research revealed that 83% of eligible adults believe there is a social stigma attached to using weight loss medication, leading more than half of users of injectables like Mounjaro or Wegovy to hide their treatment from family and friends due to fear of judgment.
The introduction of a new oral GLP-1 weight loss pill in the UK aims to offer a more discreet treatment option for individuals seeking to manage their weight. Respondents shared concerns about potential judgment, including fears of being perceived as taking shortcuts or lacking self-discipline, with many believing weight loss should only be achieved through lifestyle changes.
Despite the potential health benefits, some individuals have declined GLP-1 treatment due to practical barriers. Factors such as fear of injections, cost concerns, and worries about side effects have deterred approximately 15% of eligible adults from pursuing this form of medication. However, with the emergence of oral GLP-1 treatments, there is optimism that perceptions around weight management support will shift, providing a more cost-effective and convenient alternative for those in need.
Dr. Earim Chaudry, Chief Medical Officer at Voy, emphasized the significance of the new oral GLP-1 medication as a step towards expanding treatment options and addressing barriers to care. While the introduction of oral medication may help reduce visible signs of treatment, Dr. Chaudry highlighted the importance of challenging societal attitudes towards obesity, emphasizing the need for a comprehensive shift in how the condition is perceived and discussed.
The study also revealed that over two thirds of eligible adults would prefer a daily oral weight loss medication over a weekly injection, indicating a growing preference for more accessible and convenient treatment methods. Dr. Chaudry stressed the importance of evolving treatment options to combat the stigma surrounding obesity, emphasizing the need for a broader societal shift in understanding and addressing this complex issue.
